1932

Abstract

Impulsive-compulsive behaviors (ICBs) in Parkinson's disease (PD) are a common and devastating side effect of dopamine replacement therapy. In this review we describe the phenomenology, prevalence, and risk factors of patients with PD. Results of behavioral studies assessing the neuropsychological profile of patients with PD emphasize that the ICBs, which are behavioral addictions, are not hedonically motivated. Rather, other factors such as the inability to cope with uncertainty may be triggering ICBs. New insights from functional imaging studies, strengthening the incentive salience hypothesis, are discussed, and therapeutic guidelines for the management of ICBs in PD are given.

Loading

Article metrics loading...

/content/journals/10.1146/annurev-clinpsy-032813-153705
2014-03-28
2024-04-22
Loading full text...

Full text loading...

/deliver/fulltext/clinpsy/10/1/annurev-clinpsy-032813-153705.html?itemId=/content/journals/10.1146/annurev-clinpsy-032813-153705&mimeType=html&fmt=ahah

Literature Cited

  1. Ahlskog JE. 2011. Pathological behaviors provoked by dopamine agonist therapy of Parkinson's disease. Physiol. Behav. 104:168–72 [Google Scholar]
  2. Am. Psychiatr. Assoc 2013. Diagnostic and Statistical Manual of Mental Disorders. Washington, DC: Am. Psychiatr. Publ, 5th ed..
  3. Antonini A, Siri C, Santangelo G, Cilia R, Poletti M. et al. 2011. Impulsivity and compulsivity in drug-naive patients with Parkinson's disease. Mov. Disord. 26:464–68 [Google Scholar]
  4. Ardouin C, Voon V, Worbe Y, Abouazar N, Czernecki V. et al. 2006. Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation. Mov. Disord. 21:1941–46 [Google Scholar]
  5. Averbeck BB, Djamshidian A, O'Sullivan SS, Housden CR, Roiser JP, Lees AJ. 2013. Uncertainty about mapping future actions into rewards may underlie performance on multiple measures of impulsivity in behavioral addiction: evidence from Parkinson's disease. Behav. Neurosci. 127:245–55 [Google Scholar]
  6. Avila A, Cardona X, Bello J, Maho P, Sastre F, Martin-Baranera M. 2011. Impulse control disorders and punding in Parkinson's disease: the need for a structured interview. Neurologia 26:166–72 [Google Scholar]
  7. Bastiaens J, Dorfman BJ, Christos PJ, Nirenberg MJ. 2013. Prospective cohort study of impulse control disorders in Parkinson's disease. Mov. Disord. 28:327–33 [Google Scholar]
  8. Bechara A, Damasio AR, Damasio H, Anderson SW. 1994. Insensitivity to future consequences following damage to human prefrontal cortex. Cognition 50:7–15 [Google Scholar]
  9. Bermejo PE. 2008. Topiramate in managing impulse control disorders in Parkinson's disease. Parkinsonism Relat. Disord. 14:448–49 [Google Scholar]
  10. Bermejo PE, Ruiz-Huete C, Anciones B. 2010. Zonisamide in managing impulse control disorders in Parkinson's disease. J. Neurol. 257:1682–85 [Google Scholar]
  11. Berridge KC. 2007. The debate over dopamine's role in reward: the case for incentive salience. Psychopharmacology (Berl.) 191:391–431 [Google Scholar]
  12. Bienfait KL, Menza M, Mark MH, Dobkin RD. 2010. Impulsive smoking in a patient with Parkinson's disease treated with dopamine agonists. J. Clin. Neurosci. 17:539–40 [Google Scholar]
  13. Blanco C, Petkova E, Ibanez A, Saiz-Ruiz J. 2002. A pilot placebo-controlled study of fluvoxamine for pathological gambling. Ann. Clin. Psychiatry 14:9–15 [Google Scholar]
  14. Bodi N, Keri S, Nagy H, Moustafa A, Myers CE. et al. 2009. Reward-learning and the novelty-seeking personality: a between- and within-subjects study of the effects of dopamine agonists on young Parkinson's patients. Brain 132:2385–95 [Google Scholar]
  15. Bortolato M, Cannas A, Solla P, Bini V, Puligheddu M, Marrosu F. 2012. Finasteride attenuates pathological gambling in patients with Parkinson disease. J. Clin. Psychopharmacol. 32:424–25 [Google Scholar]
  16. Bosco D, Plastino M, Colica C, Bosco F, Arianna S. et al. 2012. Opioid antagonist naltrexone for the treatment of pathological gambling in Parkinson disease. Clin. Neuropharmacol. 35:118–20 [Google Scholar]
  17. Broen M, Duits A, Visser-Vandewalle V, Temel Y, Winogrodzka A. 2011. Impulse control and related disorders in Parkinson's disease patients treated with bilateral subthalamic nucleus stimulation: a review. Parkinsonism Relat. Disord. 17:413–17 [Google Scholar]
  18. Canesi M, Rusconi ML, Isaias IU, Pezzoli G. 2012. Artistic productivity and creative thinking in Parkinson's disease. Eur. J. Neurol. 19:468–72 [Google Scholar]
  19. Chakrabarty K, Bhattacharyya S, Christopher R, Khanna S. 2005. Glutamatergic dysfunction in OCD. Neuropsychopharmacology 30:1735–40 [Google Scholar]
  20. Cheng HC, Ulane CM, Burke RE. 2010. Clinical progression in Parkinson disease and the neurobiology of axons. Ann. Neurol. 67:715–25 [Google Scholar]
  21. Cilia R, Siri C, Marotta G, Isaias IU, De Gaspari D. et al. 2008. Functional abnormalities underlying pathological gambling in Parkinson disease. Arch. Neurol. 65:1604–11 [Google Scholar]
  22. Clark L, Robbins TW, Ersche KD, Sahakian BJ. 2006. Reflection impulsivity in current and former substance users. Biol. Psychiatry 60:515–22 [Google Scholar]
  23. Cools R, Barker RA, Sahakian BJ, Robbins TW. 2001. Enhanced or impaired cognitive function in Parkinson's disease as a function of dopaminergic medication and task demands. Cereb. Cortex 11:1136–43 [Google Scholar]
  24. Cormier F, Muellner J, Corvol JC. 2013. Genetics of impulse control disorders in Parkinson's disease. J. Neural Transm. 120:665–71 [Google Scholar]
  25. Cornelius JR, Tippmann-Peikert M, Slocumb NL, Frerichs CF, Silber MH. 2010. Impulse control disorders with the use of dopaminergic agents in restless legs syndrome: a case-control study. Sleep 33:81–87 [Google Scholar]
  26. Dagher A, Robbins TW. 2009. Personality, addiction, dopamine: insights from Parkinson's disease. Neuron 61:502–10 [Google Scholar]
  27. Dalley JW, Everitt BJ, Robbins TW. 2011. Impulsivity, compulsivity, and top-down cognitive control. Neuron 69:680–94 [Google Scholar]
  28. Dalley JW, Roiser JP. 2012. Dopamine, serotonin and impulsivity. Neuroscience 215:42–58 [Google Scholar]
  29. de Lau LM, Breteler MM. 2006. Epidemiology of Parkinson's disease. Lancet Neurol. 5:525–35 [Google Scholar]
  30. Delaney M, Leroi I, Simpson J, Overton PG. 2012. Impulse control disorders in Parkinson's disease: a psychosocial perspective. J. Clin. Psychol. Med. Settings 19:338–46 [Google Scholar]
  31. Dickman SJ. 1990. Functional and dysfunctional impulsivity: personality and cognitive correlates. J. Personal. Soc. Psychol. 58:95–102 [Google Scholar]
  32. Djamshidian A, Averbeck BB, Lees AJ, O'Sullivan SS. 2011a. Clinical aspects of impulsive compulsive behaviours in Parkinson's disease. J. Neurol. Sci. 310:183–88 [Google Scholar]
  33. Djamshidian A, Cardoso F, Grosset D, Bowden-Jones H, Lees AJ. 2011b. Pathological gambling in Parkinson's disease—a review of the literature. Mov. Disord. 26:1976–84 [Google Scholar]
  34. Djamshidian A, Jha A, O'Sullivan SS, Silveira-Moriyama L, Jacobson C. et al. 2010. Risk and learning in impulsive and nonimpulsive patients with Parkinson's disease. Mov. Disord. 25:2203–10 [Google Scholar]
  35. Djamshidian A, O'Sullivan SS, Doherty K, Lees AJ, Averbeck BB. 2011c. Altruistic punishment in patients with Parkinson's disease with and without impulsive behaviour. Neuropsychologia 49:103–7 [Google Scholar]
  36. Djamshidian A, O'Sullivan SS, Foltynie T, Aviles-Olmos I, Limousin P. et al. 2013. Dopamine agonists rather than deep brain stimulation cause reflection impulsivity in Parkinson's disease. J. Parkinson's Dis. 3:139–44 [Google Scholar]
  37. Djamshidian A, O'Sullivan SS, Lees A, Averbeck BB. 2011d. Stroop test performance in impulsive and non impulsive patients with Parkinson's disease. Parkinsonism Relat. Disord. 17:212–14 [Google Scholar]
  38. Djamshidian A, O'Sullivan SS, Lees A, Averbeck BB. 2012a. Effects of dopamine on sensitivity to social bias in Parkinson's disease. PLoS ONE 7:e32889 [Google Scholar]
  39. Djamshidian A, O'Sullivan SS, Papadopoulos A, Bassett P, Shaw K. et al. 2011e. Salivary cortisol levels in Parkinson's disease and its correlation to risk behaviour. J. Neurol. Neurosurg. Psychiatry 82:1107–11 [Google Scholar]
  40. Djamshidian A, O'Sullivan SS, Sanotsky Y, Sharman S, Matviyenko Y. et al. 2012b. Decision making, impulsivity, and addictions: Do Parkinson's disease patients jump to conclusions?. Mov. Disord. 27:1137–45 [Google Scholar]
  41. Djamshidian A, O'Sullivan SS, Wittmann BC, Lees AJ, Averbeck BB. 2011f. Novelty seeking behaviour in Parkinson's disease. Neuropsychologia 49:2483–8 [Google Scholar]
  42. Evans AH, Katzenschlager R, Paviour D, O'Sullivan JD, Appel S. et al. 2004. Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome. Mov. Disord. 19:397–405 [Google Scholar]
  43. Evans AH, Lawrence AD, Potts J, Appel S, Lees AJ. 2005. Factors influencing susceptibility to compulsive dopaminergic drug use in Parkinson disease. Neurology 65:1570–74 [Google Scholar]
  44. Evans AH, Lawrence AD, Potts J, MacGregor L, Katzenschlager R. et al. 2006a. Relationship between impulsive sensation seeking traits, smoking, alcohol and caffeine intake, and Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 77:317–21 [Google Scholar]
  45. Evans AH, Lees AJ. 2004. Dopamine dysregulation syndrome in Parkinson's disease. Curr. Opin. Neurol. 17:393–98 [Google Scholar]
  46. Evans AH, Pavese N, Lawrence AD, Tai YF, Appel S. et al. 2006b. Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Ann. Neurol. 59:852–58 [Google Scholar]
  47. Evans AH, Strafella AP, Weintraub D, Stacy M. 2009. Impulsive and compulsive behaviors in Parkinson's disease. Mov. Disord. 24:1561–70 [Google Scholar]
  48. Evenden JL. 1999. Varieties of impulsivity. Psychopharmacology (Berl.) 146:348–61 [Google Scholar]
  49. Fan W, Ding H, Ma J, Chan P. 2009. Impulse control disorders in Parkinson's disease in a Chinese population. Neurosci. Lett. 465:6–9 [Google Scholar]
  50. Fasano A, Ricciardi L, Pettorruso M, Bentivoglio AR. 2011. Management of punding in Parkinson's disease: an open-label prospective study. J. Neurol. 258:656–60 [Google Scholar]
  51. Franco C, Paris JJ, Wulfert E, Frye CA. 2009. Male gamblers have significantly greater salivary cortisol before and after betting on a horse race, than do female gamblers. Physiol. Behav. 99:225–29 [Google Scholar]
  52. Frank MJ, Samanta J, Moustafa AA, Sherman SJ. 2007. Hold your horses: impulsivity, deep brain stimulation, and medication in parkinsonism. Science 318:1309–12 [Google Scholar]
  53. Frank MJ, Seeberger LC, O'Reilly R C. 2004. By carrot or by stick: cognitive reinforcement learning in parkinsonism. Science 306:1940–3 [Google Scholar]
  54. Friedman JH. 1994. Punding on levodopa. Biol. Psychiatry 36:350–51 [Google Scholar]
  55. Friedman JH, Chang V. 2013. Crack cocaine use due to dopamine agonist therapy in Parkinson disease. Neurology 80:2269–70 [Google Scholar]
  56. Frosini D, Pesaresi I, Cosottini M, Belmonte G, Rossi C. et al. 2010. Parkinson's disease and pathological gambling: results from a functional MRI study. Mov. Disord. 25:2449–53 [Google Scholar]
  57. Furl N, Averbeck BB. 2011. Parietal cortex and insula relate to evidence seeking relevant to reward-related decisions. J. Neurosci. 31:17572–82 [Google Scholar]
  58. Gallagher DA, O'Sullivan SS, Evans AH, Lees AJ, Schrag A. 2007. Pathological gambling in Parkinson's disease: risk factors and differences from dopamine dysregulation. An analysis of published case series. Mov. Disord. 22:1757–63 [Google Scholar]
  59. Gerlach M, Double K, Arzberger T, Leblhuber F, Tatschner T, Riederer P. 2003. Dopamine receptor agonists in current clinical use: comparative dopamine receptor binding profiles defined in the human striatum. J. Neural Transm. 110:1119–27 [Google Scholar]
  60. Giovannoni G, O'Sullivan JD, Turner K, Manson AJ, Lees AJ. 2000. Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J. Neurol. Neurosurg. Psychiatry 68:423–28 [Google Scholar]
  61. Goeders NE. 2002. Stress and cocaine addiction. J. Pharmacol. Exp. Ther. 301:785–89 [Google Scholar]
  62. Gotham AM, Brown RG, Marsden CD. 1988. “Frontal” cognitive function in patients with Parkinson's disease “on” and “off” levodopa. Brain 111:Part 2299–321 [Google Scholar]
  63. Grant JE, Chamberlain SR, Odlaug BL, Potenza MN, Kim SW. 2010. Memantine shows promise in reducing gambling severity and cognitive inflexibility in pathological gambling: a pilot study. Psychopharmacology (Berl.) 212:603–12 [Google Scholar]
  64. Grant JE, Odlaug BL, Kim SW. 2009. N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study. Arch. Gen. Psychiatry 66:756–63 [Google Scholar]
  65. Gurevich EV, Joyce JN. 1999. Distribution of dopamine D3 receptor expressing neurons in the human forebrain: comparison with D2 receptor expressing neurons. Neuropsychopharmacology 20:60–80 [Google Scholar]
  66. Halbig TD, Tse W, Frisina PG, Baker BR, Hollander E. et al. 2009. Subthalamic deep brain stimulation and impulse control in Parkinson's disease. Eur. J. Neurol. 16:493–97 [Google Scholar]
  67. Hardman CD, Henderson JM, Finkelstein DI, Horne MK, Paxinos G, Halliday GM. 2002. Comparison of the basal ganglia in rats, marmosets, macaques, baboons, and humans: volume and neuronal number for the output, internal relay, and striatal modulating nuclei. J. Comp. Neurol. 445:238–55 [Google Scholar]
  68. Hassan A, Bower JH, Kumar N, Matsumoto JY, Fealey RD. et al. 2011. Dopamine agonist-triggered pathological behaviors: Surveillance in the PD clinic reveals high frequencies. Parkinsonism Relat. Disord. 17:260–64 [Google Scholar]
  69. Hirtz D, Thurman DJ, Gwinn-Hardy K, Mohamed M, Chaudhuri AR, Zalutsky R. 2007. How common are the “common” neurologic disorders?. Neurology 68:326–37 [Google Scholar]
  70. Hoerst M, Weber-Fahr W, Tunc-Skarka N, Ruf M, Bohus M. et al. 2010. Correlation of glutamate levels in the anterior cingulate cortex with self-reported impulsivity in patients with borderline personality disorder and healthy controls. Arch. Gen. Psychiatry 67:946–54 [Google Scholar]
  71. Housden CR, O'Sullivan SS, Joyce EM, Lees AJ, Roiser JP. 2010. Intact reward learning but elevated delay discounting in Parkinson's disease patients with impulsive-compulsive spectrum behaviors. Neuropsychopharmacology 35:2155–64 [Google Scholar]
  72. Joutsa J, Martikainen K, Niemela S, Johansson J, Forsback S. et al. 2012a. Increased medial orbitofrontal [18F]fluorodopa uptake in Parkinsonian impulse control disorders. Mov. Disord. 27:778–82 [Google Scholar]
  73. Joutsa J, Martikainen K, Vahlberg T, Kaasinen V. 2012b. Effects of dopamine agonist dose and gender on the prognosis of impulse control disorders in Parkinson's disease. Parkinsonism Relat. Disord. 18:1079–83 [Google Scholar]
  74. Joutsa J, Martikainen K, Vahlberg T, Voon V, Kaasinen V. 2012c. Impulse control disorders and depression in Finnish patients with Parkinson's disease. Parkinsonism Relat. Disord. 18:155–60 [Google Scholar]
  75. Kagan J. 1966. Reflection-impulsivity: the generality and dynamics of conceptual tempo. J. Abnorm. Psychol. 71:17–24 [Google Scholar]
  76. Kalivas PW. 2009. The glutamate homeostasis hypothesis of addiction. Nat. Rev. Neurosci. 10:561–72 [Google Scholar]
  77. Kirby KN, Petry NM, Bickel WK. 1999. Heroin addicts have higher discount rates for delayed rewards than non-drug-using controls. J. Exp. Psychol. Gen. 128:78–87 [Google Scholar]
  78. Kish SJ, Shannak K, Hornykiewicz O. 1988. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N. Engl. J. Med. 318:876–80 [Google Scholar]
  79. Koob GF, Volkow ND. 2010. Neurocircuitry of addiction. Neuropsychopharmacology 35:217–38 [Google Scholar]
  80. Langer EJ. 1975. The illusion of control. J. Personal. Soc. Psychol. 32:311–28 [Google Scholar]
  81. Lee JY, Jeon BS, Kim HJ, Park SS. 2012. Genetic variant of HTR2A associates with risk of impulse control and repetitive behaviors in Parkinson's disease. Parkinsonism Relat. Disord. 18:76–78 [Google Scholar]
  82. Lee JY, Kim HJ, Jeon BS. 2011. Is pathological gambling in Parkinson's disease reduced by amantadine?. Ann. Neurol. 69:213–14 author reply 214–15 [Google Scholar]
  83. Lee JY, Kim JM, Kim JW, Cho J, Lee WY. et al. 2009. Association between the dose of dopaminergic medication and the behavioral disturbances in Parkinson disease. Parkinsonism Relat. Disord. 16:202–7 [Google Scholar]
  84. Lees AJ, Hardy J, Revesz T. 2009. Parkinson's disease. Lancet 373:2055–66 [Google Scholar]
  85. Leroi I, Ahearn DJ, Andrews M, McDonald KR, Byrne EJ, Burns A. 2011. Behavioural disorders, disability and quality of life in Parkinson's disease. Age Ageing 40:614–21 [Google Scholar]
  86. Leroi I, Harbishettar V, Andrews M, McDonald K, Byrne EJ, Burns A. 2012. Carer burden in apathy and impulse control disorders in Parkinson's disease. Int. J. Geriatr. Psychiatry 27:160–66 [Google Scholar]
  87. Lhommee E, Klinger H, Thobois S, Schmitt E, Ardouin C. et al. 2012. Subthalamic stimulation in Parkinson's disease: restoring the balance of motivated behaviours. Brain 135:1463–77 [Google Scholar]
  88. Lim SY, O'Sullivan SS, Kotschet K, Gallagher DA, Lacey C. et al. 2009. Dopamine dysregulation syndrome, impulse control disorders and punding after deep brain stimulation surgery for Parkinson's disease. J. Clin. Neurosci. 16:1148–52 [Google Scholar]
  89. Lovallo WR. 2006. Cortisol secretion patterns in addiction and addiction risk. Int. J. Psychophysiol. 59:195–202 [Google Scholar]
  90. Lu C, Bharmal A, Suchowersky O. 2006. Gambling and Parkinson disease. Arch. Neurol. 63:298 [Google Scholar]
  91. Macphee GJ, Copeland C, Stewart D, Grosset K, Grosset DG. 2009. Clinical follow up of pathological gambling in Parkinson's disease in the West Scotland study. Mov. Disord. 24:2430–31 [Google Scholar]
  92. Mamikonyan E, Siderowf AD, Duda JE, Potenza MN, Horn S. et al. 2008. Long-term follow-up of impulse control disorders in Parkinson's disease. Mov. Disord. 23:75–80 [Google Scholar]
  93. McElroy SL, Keck PE Jr, Pope HG Jr, Smith JM, Strakowski SM. 1994. Compulsive buying: a report of 20 cases. J. Clin. Psychiatry 55:242–48 [Google Scholar]
  94. McElroy SL, Nelson EB, Welge JA, Kaehler L, Keck PE Jr. 2008. Olanzapine in the treatment of pathological gambling: a negative randomized placebo-controlled trial. J. Clin. Psychiatry 69:433–40 [Google Scholar]
  95. McKeon A, Josephs KA, Klos KJ, Hecksel K, Bower JH. et al. 2007. Unusual compulsive behaviors primarily related to dopamine agonist therapy in Parkinson's disease and multiple system atrophy. Parkinsonism Relat. Disord. 13:516–19 [Google Scholar]
  96. Menza M. 2000. The personality associated with Parkinson's disease. Curr. Psychiatry Rep. 2:421–26 [Google Scholar]
  97. Menza MA, Golbe LI, Cody RA, Forman NE. 1993. Dopamine-related personality traits in Parkinson's disease. Neurology 43:505–8 [Google Scholar]
  98. Mestre T, Strafella AP, Thomsen T, Voon V, Miyasaki J. 2013. Diagnosis and treatment of impulse control disorders in patients with movement disorders. Ther. Adv. Neurol. Disord. 6:175–88 [Google Scholar]
  99. Meyer G, Hauffa BP, Schedlowski M, Pawlak C, Stadler MA, Exton MS. 2000. Casino gambling increases heart rate and salivary cortisol in regular gamblers. Biol. Psychiatry 48:948–53 [Google Scholar]
  100. Milenkova M, Mohammadi B, Kollewe K, Schrader C, Fellbrich A. et al. 2011. Intertemporal choice in Parkinson's disease. Mov. Disord. 26:2004–10 [Google Scholar]
  101. Moum SJ, Price CC, Limotai N, Oyama G, Ward H. et al. 2012. Effects of STN and GPi deep brain stimulation on impulse control disorders and dopamine dysregulation syndrome. PLoS ONE 7:e29768 [Google Scholar]
  102. Muresanu DF, Stan A, Buzoianu A. 2012. Neuroplasticity and impulse control disorders. J. Neurol. Sci. 316:15–20 [Google Scholar]
  103. O'Sullivan SS, Djamshidian A, Ahmed Z, Evans AH, Lawrence AD. et al. 2010a. Impulsive-compulsive spectrum behaviors in pathologically confirmed progressive supranuclear palsy. Mov. Disord. 25:638–42 [Google Scholar]
  104. O'Sullivan SS, Djamshidian A, Evans AH, Loane CM, Lees AJ, Lawrence AD. 2010b. Excessive hoarding in Parkinson's disease. Mov. Disord. 25:1026–33 [Google Scholar]
  105. O'Sullivan SS, Evans AH, Lees AJ. 2007. Punding in Parkinson's disease. Pract. Neurol. 7:397–99 [Google Scholar]
  106. O'Sullivan SS, Evans AH, Lees AJ. 2009. Dopamine dysregulation syndrome: an overview of its epidemiology, mechanisms and management. CNS Drugs 23:157–70 [Google Scholar]
  107. O'Sullivan SS, Evans AH, Quinn NP, Lawrence AD, Lees AJ. 2010c. Reckless generosity in Parkinson's disease. Mov. Disord. 25:221–23 [Google Scholar]
  108. O'Sullivan SS, Loane CM, Lawrence AD, Evans AH, Piccini P, Lees AJ. 2010d. Sleep disturbance and impulsive-compulsive behaviours in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 82:620–22 [Google Scholar]
  109. O'Sullivan SS, Wu K, Politis M, Lawrence AD, Evans AH. et al. 2011. Cue-induced striatal dopamine release in Parkinson's disease-associated impulsive-compulsive behaviours. Brain 134:969–78 [Google Scholar]
  110. Okai D, Askey-Jones S, Samuel M, O'Sullivan SS, Chaudhuri KR. et al. 2013. Trial of CBT for impulse control behaviors affecting Parkinson patients and their caregivers. Neurology 80:792–99 [Google Scholar]
  111. Papay K, Mamikonyan E, Siderowf AD, Duda JE, Lyons KE. et al. 2011. Patient versus informant reporting of ICD symptoms in Parkinson's disease using the QUIP: validity and variability. Parkinsonism Relat. Disord. 17:153–55 [Google Scholar]
  112. Parkinson J. 1817. An Essay on the Shaking Palsy London: Sherwood, Neely, Jones
  113. Patton JH, Stanford MS, Barratt ES. 1995. Factor structure of the Barratt impulsiveness scale. J. Clin. Psychol. 51:768–74 [Google Scholar]
  114. Petry NM, Stinson FS, Grant BF. 2005. Comorbidity of DSM-IV pathological gambling and other psychiatric disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J. Clin. Psychiatry 66:564–74 [Google Scholar]
  115. Poletti M, Bonuccelli U. 2012. Personality traits in patients with Parkinson's disease: assessment and clinical implications. J. Neurol. 259:1029–38 [Google Scholar]
  116. Poletti M, Frosini D, Pagni C, Claudio L, Paolo del D. et al. 2012. Alexithymia is associated with impulsivity in newly-diagnosed, drug-naive patients with Parkinson's disease: an affective risk factor for the development of impulse-control disorders?. J. Neuropsychiatry Clin. Neurosci. 24:E36–37 [Google Scholar]
  117. Politis M, Loane C, Wu K, O'Sullivan SS, Woodhead Z. et al. 2013. Neural response to visual sexual cues in dopamine treatment-linked hypersexuality in Parkinson's disease. Brain 136:400–11 [Google Scholar]
  118. Pondal M, Marras C, Miyasaki J, Moro E, Armstrong MJ. et al. 2013. Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic. J. Neurol. Neurosurg. Psychiatry 84:130–35 [Google Scholar]
  119. Rabinak CA, Nirenberg MJ. 2010. Dopamine agonist withdrawal syndrome in Parkinson disease. Arch. Neurol. 67:58–63 [Google Scholar]
  120. Raina G, Cersosimo MG, Micheli F. 2012. Zoophilia and impulse control disorder in a patient with Parkinson disease. J. Neurol. 259:969–70 [Google Scholar]
  121. Ray NJ, Miyasaki JM, Zurowski M, Ko JH, Cho SS. et al. 2012. Extrastriatal dopaminergic abnormalities of DA homeostasis in Parkinson's patients with medication-induced pathological gambling: a [11C] FLB-457 and PET study. Neurobiol. Dis. 48:519–25 [Google Scholar]
  122. Richard IH, McDermott MP, Kurlan R, Lyness JM, Como PG. et al. 2012. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology 78:1229–36 [Google Scholar]
  123. Rizos A, Martinez-Martin P, Martin A, Henriksen T, Kessel B. et al. 2012. European multicentre survey of tolerability rates and impulse control behaviour trends of prolonged release dopamine agonists in young and old PD. Mov. Disord. 27:Suppl. 1161 (Abstr.) [Google Scholar]
  124. Robbins TW, Gillan CM, Smith DG, de Wit S, Ersche KD. 2012. Neurocognitive endophenotypes of impulsivity and compulsivity: towards dimensional psychiatry. Trends Cogn. Sci. 16:81–91 [Google Scholar]
  125. Robinson TE, Berridge KC. 2008. Review. The incentive sensitization theory of addiction: some current issues. Philos. Trans. R. Soc. B 363:3137–46 [Google Scholar]
  126. Rodriguez-Oroz MC, Lopez-Azcarate J, Garcia-Garcia D, Alegre M, Toledo J. et al. 2010. Involvement of the subthalamic nucleus in impulse control disorders associated with Parkinson's disease. Brain 134:36–49 [Google Scholar]
  127. Rogers RD, Wielenberg B, Wojtecki L, Elben S, Campbell-Meiklejohn D, Schnitzler A. 2011. Deep brain stimulation of the subthalamic nucleus transiently enhances loss-chasing behaviour in patients with Parkinson's disease. Exp. Neurol. 231:181–89 [Google Scholar]
  128. Rossi M, Gerschcovich ER, de Achaval D, Perez-Lloret S, Cerquetti D. et al. 2010. Decision-making in Parkinson's disease patients with and without pathological gambling. Eur. J. Neurol. 17:97–102 [Google Scholar]
  129. Rylander G. 1972. Psychoses and the punding and choreiform syndromes in addiction to central stimulant drugs. Psychiatr. Neurol. Neurochir. 75:203–12 [Google Scholar]
  130. Saint-Cyr JA, Hoque T, Pereira LC, Dostrovsky JO, Hutchison WD. et al. 2002. Localization of clinically effective stimulating electrodes in the human subthalamic nucleus on magnetic resonance imaging. J. Neurosurg. 97:1152–66 [Google Scholar]
  131. Scheller D, Ullmer C, Berkels R, Gwarek M, Lübbert H. 2009. The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson's disease. Naunyn Schmeidebergs Arch. Pharmacol. 379:73–86 [Google Scholar]
  132. Schwingenschuh P, Katschnig P, Saurugg R, Ott E, Bhatia KP. 2010. Artistic profession: a potential risk factor for dopamine dysregulation syndrome in Parkinson's disease?. Mov. Disord. 25:493–96 [Google Scholar]
  133. Seppi K, Weintraub D, Coelho M, Perez-Lloret S, Fox SH. et al. 2011. The Movement Disorder Society Evidence-Based Medicine Review update: treatments for the non-motor symptoms of Parkinson's disease. Mov. Disord. 26:Suppl. 3S42–80 [Google Scholar]
  134. Sevincok L, Akoglu A, Akyol A. 2007. Quetiapine in a case with Parkinson disease and pathological gambling. J. Clin. Psychopharmacol. 27:107–8 [Google Scholar]
  135. Sgambato-Faure V, Cenci MA. 2012. Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease. Prog. Neurobiol. 96:69–86 [Google Scholar]
  136. Shiner T, Seymour B, Wunderlich K, Hill C, Bhatia KP. et al. 2012. Dopamine and performance in a reinforcement learning task: evidence from Parkinson's disease. Brain 135:1871–83 [Google Scholar]
  137. Silveira-Moriyama L, Evans AH, Katzenschlager R, Lees AJ. 2006. Punding and dyskinesias. Mov. Disord. 21:2214–17 [Google Scholar]
  138. Singh A, Kandimala G, Dewey RB Jr, O'Suilleabhain P. 2007. Risk factors for pathologic gambling and other compulsions among Parkinson's disease patients taking dopamine agonists. J. Clin. Neurosci. 14:1178–81 [Google Scholar]
  139. Siri C, Cilia R, De Gaspari D, Canesi M, Meucci N. et al. 2010. Cognitive status of patients with Parkinson's disease and pathological gambling. J. Neurol. 257:247–52 [Google Scholar]
  140. Sohtaoglu M, Demiray DY, Kenangil G, Ozekmekci S, Erginoz E. 2010. Long term follow-up of Parkinson's disease patients with impulse control disorders. Parkinsonism Relat. Disord. 16:334–37 [Google Scholar]
  141. Sokoloff P, Giros B, Martres MP, Bouthenet ML, Schwartz JC. 1990. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 347:146–51 [Google Scholar]
  142. Solla P, Cannas A, Marrosu MG, Marrosu F. 2012. Dopaminergic-induced paraphilias associated with impulse control and related disorders in patients with Parkinson disease. J. Neurol. 259:2752–54 [Google Scholar]
  143. Sriram A, Ward HE, Hassan A, Iyer S, Foote KD. et al. 2013. Valproate as a treatment for dopamine dysregulation syndrome (DDS) in Parkinson's disease. J. Neurol. 260:521–27 [Google Scholar]
  144. Steeves TD, Miyasaki J, Zurowski M, Lang AE, Pellecchia G. et al. 2009. Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study. Brain 132:1376–85 [Google Scholar]
  145. Thomas A, Bonanni L, Gambi F, Di Iorio A, Onofrj M. 2010. Pathological gambling in Parkinson disease is reduced by amantadine. Ann. Neurol. 68:400–4 [Google Scholar]
  146. Vallelunga A, Flaibani R, Formento-Dojot P, Biundo R, Facchini S, Antonini A. 2012. Role of genetic polymorphisms of the dopaminergic system in Parkinson's disease patients with impulse control disorders. Parkinsonism Relat. Disord. 18:397–99 [Google Scholar]
  147. van Eimeren T, Ballanger B, Pellecchia G, Miyasaki JM, Lang AE, Strafella AP. 2009. Dopamine agonists diminish value sensitivity of the orbitofrontal cortex: a trigger for pathological gambling in Parkinson's disease?. Neuropsychopharmacology 34:2758–66 [Google Scholar]
  148. Verdejo-Garcia A, Lawrence AJ, Clark L. 2008. Impulsivity as a vulnerability marker for substance-use disorders: review of findings from high-risk research, problem gamblers and genetic association studies. Neurosci. Biobehav. Rev. 32:777–810 [Google Scholar]
  149. Vitale C, Santangelo G, Erro R, Errico D, Manganelli F. et al. 2013. Impulse control disorders induced by rasagiline as adjunctive therapy for Parkinson's disease: report of 2 cases. Parkinsonism Relat. Disord. 19:483–84 [Google Scholar]
  150. Vlaar A, Hovestadt A, van Laar T, Bloem BR. 2011. The treatment of early Parkinson's disease: levodopa rehabilitated. Pract. Neurol. 11:145–52 [Google Scholar]
  151. Volkow ND, Wang GJ, Fischman MW, Foltin RW, Fowler JS. et al. 1997. Relationship between subjective effects of cocaine and dopamine transporter occupancy. Nature 386:827–30 [Google Scholar]
  152. Volkow ND, Wang GJ, Fowler JS, Telang F. 2008. Overlapping neuronal circuits in addiction and obesity: evidence of systems pathology. Philos. Trans. R. Soc. B 363:3191–200 [Google Scholar]
  153. Voon V, Fernagut PO, Wickens J, Baunez C, Rodriguez M. et al. 2009. Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders. Lancet Neurol. 8:1140–49 [Google Scholar]
  154. Voon V, Hassan K, Zurowski M, de Souza M, Thomsen T. et al. 2006. Prevalence of repetitive and reward-seeking behaviors in Parkinson disease. Neurology 67:1254–57 [Google Scholar]
  155. Voon V, Mehta AR, Hallett M. 2011a. Impulse control disorders in Parkinson's disease: recent advances. Curr. Opin. Neurol. 24:324–30 [Google Scholar]
  156. Voon V, Pessiglione M, Brezing C, Gallea C, Fernandez HH. et al. 2010a. Mechanisms underlying dopamine-mediated reward bias in compulsive behaviors. Neuron 65:135–42 [Google Scholar]
  157. Voon V, Reynolds B, Brezing C, Gallea C, Skaljic M. et al. 2010b. Impulsive choice and response in dopamine agonist-related impulse control behaviors. Psychopharmacology (Berl.) 207:645–59 [Google Scholar]
  158. Voon V, Sohr M, Lang AE, Potenza MN, Siderowf AD. et al. 2011b. Impulse control disorders in Parkinson disease: a multicenter case-control study. Ann. Neurol. 69:986–96 [Google Scholar]
  159. Voon V, Thomsen T, Miyasaki JM, de Souza M, Shafro A. et al. 2007. Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease. Arch. Neurol. 64:212–16 [Google Scholar]
  160. Weintraub D, Hoops S, Shea JA, Lyons KE, Pahwa R. et al. 2009. Validation of the questionnaire for impulsive-compulsive disorders in Parkinson's disease. Mov. Disord. 24:1461–67 [Google Scholar]
  161. Weintraub D, Koester J, Potenza MN, Siderowf AD, Stacy M. et al. 2010a. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch. Neurol. 67:589–95 [Google Scholar]
  162. Weintraub D, Papay K, Siderowf A. 2013. Screening for impulse control symptoms in patients with de novo Parkinson disease: a case-control study. Neurology 80:176–80 [Google Scholar]
  163. Weintraub D, Sohr M, Potenza MN, Siderowf AD, Stacy M. et al. 2010b. Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. Ann. Neurol. 68:963–68 [Google Scholar]
  164. Willis AW, Schootman M, Kung N, Racette BA. 2013. Epidemiology and neuropsychiatric manifestations of young onset Parkinson's disease in the United States. Parkinsonism Relat. Disord. 19:202–6 [Google Scholar]
  165. Wittmann BC, Daw ND, Seymour B, Dolan RJ. 2008. Striatal activity underlies novelty-based choice in humans. Neuron 58:967–73 [Google Scholar]
  166. Wylie SA, Claassen DO, Huizenga HM, Schewel KD, Ridderinkhof KR. et al. 2012a. Dopamine agonists and the suppression of impulsive motor actions in Parkinson disease. J. Cogn. Neurosci. 24:1709–24 [Google Scholar]
  167. Wylie SA, van den Wildenberg W, Ridderinkhof KR, Claassen DO, Wooten GF, Manning CA. 2012b. Differential susceptibility to motor impulsivity among functional subtypes of Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 83:1149–54 [Google Scholar]
  168. Zahodne LB, Susatia F, Bowers D, Ong TL, Jacobson CE 4th. et al. 2011. Binge eating in Parkinson's disease: prevalence, correlates and the contribution of deep brain stimulation. J. Neuropsychiatry Clin. Neurosci. 23:56–62 [Google Scholar]
/content/journals/10.1146/annurev-clinpsy-032813-153705
Loading
/content/journals/10.1146/annurev-clinpsy-032813-153705
Loading

Data & Media loading...

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error